Nikolay N Zavadenko

Learn More
The objective of the study was to compare the efficacy and tolerability of once-daily atomoxetine (< or =1.8 mg/(kg day) with those of placebo in children and adolescents (aged 6-16 years) with attention-deficit/hyperactivity disorder [ADHD (DSM-IV)]. This randomized, placebo-controlled, double-blind trial was conducted in Russia. The primary efficacy(More)
The efficacy of piracetam in treating the sequelae of moderate and severe closed craniocerebral trauma (CCT) in adolescents was evaluated in studies of 42 patients aged 12-18 years who had suffered CCT 1.5-5 years prior to the study. Adolescents of the experimental group (20 individuals) received piracetam (Nootropil) at doses of 40-50 mg/kg (daily daily(More)
To assess objectively a dynamics of brain functional state, EEG spectral power and peak latency of the P300 component of cognitive auditory evoked potentials have been analyzed in adolescents during the course of nootropic therapy of residual asthenic consequences of traumatic brain injury (ICD-10 F07.2). The study included 76 adolescents, aged 12-18 years,(More)
Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder found in children. Comorbid disorders, including oppositional/aggressive behaviors and emotional disorders, may be present in the majority of children diagnosed with ADHD thus complicating an optimal choice of pharmacotherapy. We evaluated the comorbid disorders in an(More)
Frequency of comorbid disorders and neuropsychological state, executive functions (EF), were studied in two groups of patients aged from 5 to 14 years: 53 patients with attention-deficit hyperactivity disorder (ADHD) in the association with enuresis and 71 patients with ADHD without enuresis. The most cases of enuresis (50 out of 53 patients) were(More)
Developmental dysphasia (alalia) represents a severe speech and language disorder in children. To assess the efficacy of treatment with cerebrolysin, we have examined 60 children with developmental dysphasia, aged from 3 to 4 years. Group 1 (30 patients) received cerebrolysin (monotherapy, daily dosage 0.1 ml/kg, in the morning hours, on each other day,(More)
To assess the efficacy of treatment with encephabol, we examined 40 children, aged from 3 to 5 years, with developmental dysphasia. All patients were randomized into two equal groups: group 1 received encephabol (suspension form, daily dosage 200-250 mg, or 12-15 mg/kg) during 2 months; group 2 did not receive this medication. In the first group, there was(More)
Forty children with dyslexia, aged 7-12 years, have been randomized into two groups in an open controlled study: 18 of them received Nootropil (piracetam) in the dose of 100 mg/kg daily for 2 months and 22 were examined as a control group. Nootropil exerted positive effects on reading and spelling skills in 56% of children with dyslexia who demonstrated the(More)
Study aim. To investigate the dynamics of measures of behavior, attention, and memory during treatment with Noofen (250-mg capsules) in children with attention deficit hyperactivity disorder (ADHD). Materials and methods. A total of 50 patients taking part in an open study were divided into two groups of 25 patients: patients of group 1 received Noofen(More)